Pipeline
Pipeline
Advancing antibody therapeutics across multiple disease areas
Advancing antibody therapeutics across multiple disease areas
Program
IND-
Enabling
Phase 1
Phase 2
Phase 3
Marketed
Immuno-oncology
PSB114⁺(αCCR8)
PSB103 (αPD-1)
PSB205* (αPD-1 + αCTLA-4)
Immunology &
Inflammation
PSB234 (Undisclosed)
PSB219^
(αTSLP + αIL-33 MabPair)
Neurology
(Brain Shuttled)
PSB233 (αSynuclein)
PSB229 (anti-β amyloid)
Program
IND-
Enabling
Phase 1
Phase 2
Phase 3
Marketed
Immuno-oncology
PSB114⁺(αCCR8)
PSB103 (αPD-1)
PSB205* (αPD-1 + αCTLA-4)
Immunology &
Inflammation
PSB234 (Undisclosed)
PSB219^
(αTSLP + αIL-33 MabPair)
Neurology
(Brain Targeted)
PSB233 (αSynuclein)
PSB229 (anti-β amyloid)
More about PSB219 ➤
More about PSB219 ➤
^ PSB219 (QLP3119) Status: IND cleared for clinical studies by FDA in US and NMPA in China.
^ PSB219 (QLP3119) Status: IND cleared for clinical studies by FDA in US and NMPA in China.
More about PSB114 ➤
More about PSB114 ➤
+ PSB114 (QLP2117) Status: IND cleared by NMPA in China; Phase 1b/II clinical trials are ongoing.
+ PSB114 (QLP2117) Status: IND cleared by NMPA in China; Phase 1b/II clinical trials are ongoing.
More about PSB205 ➤
More about PSB205 ➤
* PSB205 (QL1706) Status: Approved and marketed in China to treat patients with recurrent or metastatic cervical cancer.
* PSB205 (QL1706) Status: Approved and marketed in China to treat patients with recurrent or metastatic cervical cancer.
